We are live on ! Find out more
CRSP icon

CRISPR Therapeutics
CRSP

174 hedge funds and large institutions have $1.09B invested in CRISPR Therapeutics in 2018 Q2 according to their latest regulatory filings, with 70 funds opening new positions, 52 increasing their positions, 32 reducing their positions, and 30 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more first-time investments, than exits

New positions opened: 70 | Existing positions closed: 30

63% more repeat investments, than reductions

Existing positions increased: 52 | Existing positions reduced: 32

29% more funds holding

Funds holding: 135 → 174 (+39)

27% more capital invested

Capital invested by funds: $855M → $1.09B (+$232M)

0.64% less ownership

Funds ownership: 39.84% → 39.2% (-0.64%)

20% less funds holding in top 10

Funds holding in top 10: 5 → 4 (-1)

66% less call options, than puts

Call options by funds: $29.7M | Put options by funds: $86.8M

Holders
174
Holders Change
+39
Holders Change %
+28.89%
% of All Funds
3.98%
Holding in Top 10
4
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-20%
% of All Funds
0.09%
New
70
Increased
52
Reduced
32
Closed
30
Calls
$29.7M
Puts
$86.8M
Net Calls
-$57.1M
Net Calls Change
-$35.1M

Top Buyers

1
Federated Hermes
Federated Hermes
Pennsylvania
+$36M
2
AIM
ARK Investment Management
Florida
+$22.5M
3
O
OrbiMed
New York
+$22.3M
4
Two Sigma Advisers
Two Sigma Advisers
New York
+$19M
5
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
+$12.9M

Top Sellers

1
NMC
NEA Management Company
Maryland
-$79.4M
2
VVM
Versant Venture Management
California
-$56.8M
3
A
Abingworth
United Kingdom
-$37M
4
MWNA
Marshall Wace North America
New York
-$21.8M
5
NHAS
Novo Holdings A/S
Denmark
-$10.2M
Name Holding Trade Value Shares
Change 		Change in
Stake
JRP
101
Jasper Ridge Partners
California
$322K +$312K +5,484 New
Axa
102
Axa
France
$300K +$291K +5,100 New
PCM
103
Prelude Capital Management
New York
$298K -$345K -6,053 -54%
IWM
104
IHT Wealth Management
Illinois
$297K -$28.5K -500 -9%
JMH
105
J.M. Hartwell
New York
$294K – – –
CM
106
Caption Management
Oklahoma
$294K +$285K +5,000 New
VCM
107
Vivaldi Capital Management
Illinois
$294K +$285K +5,000 New
FDCDDQ
108
Federation des caisses Desjardins du Quebec
Quebec, Canada
$272K +$201K +3,530 +321%
M&T Bank
109
M&T Bank
New York
$261K +$570 +10 +0.2%
BCM
110
BTC Capital Management
Iowa
$258K +$246K +4,323 New
PCM
111
Parsons Capital Management
Rhode Island
$243K +$235K +4,130 New
PAG
112
Private Advisor Group
New Jersey
$227K +$215K +3,775 New
Teacher Retirement System of Texas
113
Teacher Retirement System of Texas
Texas
$225K +$218K +3,832 New
AIP
114
Ahrens Investment Partners
Louisiana
$201K +$195K +3,415 New
AAMU
115
Amundi Asset Management US
Massachusetts
$188K +$22.8K +400 +14%
LTFS
116
Ladenburg Thalmann Financial Services
Florida
$186K – – –
APA
117
American Portfolios Advisors
New York
$182K +$177K +3,100 New
Zurich Cantonal Bank
118
Zurich Cantonal Bank
Switzerland
$166K +$64.2K +1,127 +66%
SWM
119
SeaCrest Wealth Management
New York
$160K +$104K +1,826 +203%
FMT
120
First Mercantile Trust
Tennessee
$141K +$137K +2,401 New
S
121
SignatureFD
Georgia
$138K +$74.1K +1,300 +124%
GT
122
Glenmede Trust
Pennsylvania
$138K +$134K +2,349 New
PCM
123
Princeton Capital Management
New Jersey
$118K – – –
Rockefeller Capital Management
124
Rockefeller Capital Management
New York
$116K +$113K +1,979 New
AIM
125
Assured Investment Management
New York
$109K -$91.9K -1,613 -46%
3 4
5
6 7

CRSP Hedge Fund Activity: Q2 2018 in Review

174 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in CRISPR Therapeutics (CRSP) for Q2 2018, worth a combined $1.09B — up 27% from $855M a quarter earlier.

Buyers outnumbered sellers: 70 funds opened new CRSP positions and 30 closed out — a net gain of 40 holders — while 52 added to existing stakes and 32 trimmed.

The largest buyer was Federated Hermes, opening a new position worth an estimated $36M. The largest seller was NEA Management Company, cutting an estimated $79.4M.

  • 174 institutional investors held CRISPR Therapeutics (CRSP) as of Q2 2018, up from 135 in Q1 2018.
  • Funds reported $1.09B of CRISPR Therapeutics stock for Q2 2018, up 27% quarter-over-quarter.
  • 70 funds opened new CRISPR Therapeutics positions in Q2 2018 and 30 closed out, a net change of +40 holders.
  • The largest CRISPR Therapeutics buyer in Q2 2018 was Federated Hermes, an estimated $36M added.
  • The largest CRISPR Therapeutics seller in Q2 2018 was NEA Management Company, an estimated $79.4M sold.

Based on aggregated 13F filings for Q2 2018.